Immunosupressive therapy in combination with hemotopoietic cell transplant was found to induce remission of Multiple Sclerosis activity for up…
Articles by Patricia Silva, PhD
Given the fact that MS is a chronic, progressive, and disabling disease for which there is no cure, the multiple sclerosis…
A team of researchers from Italy recently examined if p53 genetic variants influence synaptic and toxic effects of cytokines in…
Biopharmaceutical company Receptos, Inc. is enrolling the first patient in their SUNBEAM phase 3 trial to evaluate the…
British Columbia’s PharmaCare drug program has announced that it will fund AUBAGIO, a therapy developed by Genzyme for the treatment…
Icometrix, a biotechnology company focused on unique projects for diagnosing and treating multiple sclerosis (MS) patients, has designed new software for…
Mapi Pharma Ltd., a development stage pharmaceutical company specializing in the development of high-barrier to entry and high-added value generic drugs, announced…
A new study on the development of therapeutic monoclonal antibodies to treat neuroinflammatory and demyelinating disease entitled “…
Scientists from Amsterdam-based Motek Medical developed an innovative virtual reality system that allows clinicians to see and analyze a patient’s…
A team of researchers from Ohio State University received a $44,000 grant from the National Multiple Sclerosis Society…
Dr. Nataliya Ternopolska Pennsylvania-based Abington Health has announced that it has named Nataliya Ternopolska, M.D. as the new associate…
A team of researchers from the Case Western Reserve’s Frances Payne Bolton School of Nursing has designed a 24-week…
Israel-based biopharmaceutical company Teva Pharmaceutical Industries Ltd. announced last week that its thrice-weekly COPAXONE® (glatiramer acetate) 40mg/ml…
Actress and star of the ABC show “Revenge”, Madeleine Stowe, recently shared her personal story of living in…
Neurology and autoimmune therapeutics company GeNeuro SA has just announced the formation of a partnership with independent French pharmaceutical company Servier for the…
Keeping a journal may help patients suffering from severe and chronic diseases deal with their conditions, as well as…
Patient education, support and self-management of multiple sclerosis (MS) has just become easier through the joint efforts of…
Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for…
Teva Pharmaceutical Industries Ltd., the company behind multiple sclerosis drug COPAXONE® (glatiramer acetate injection), has been…
Luoxis Diagnostics, Inc. recently presented three clinical and preclinical findings that feature the company’s proprietary RedoxSYS™ Diagnostic System as a…
The US Food and Drug Administration has just issued a report warning the general public and healthcare providers…
Lexington, MA-based biopharmaceutical company Xenetic Biosciences, Inc. has just announced its new license partner Pharmsynthez has completed dosing in its ongoing Phase…
The Cognitive Rehabilitation for Attention and Memory trial (CRAMMS), a major study to be conducted on patients suffering from multiple…
The Alliance for Continuing Education in the Health Professions, an international membership association of healthcare education professionals, has just…
The Alliance for Children’s Therapeutics recently announced its plans to broaden its scope of research programs to include several diseases,…
For those with Multiple Sclerosis, the progressive manner in which the disease slowly deteriorates motor function, balance, and coordination…
Unconventional medical approaches and lifestyle changes may help patients suffering from multiple sclerosis (MS) improve their health and well-being,…
Teva Pharmaceutical Industries Ltd., the company that developed the injectable multiple sclerosis treatment…
One of the country’s leading non-profit multiple sclerosis organizations, the Multiple Sclerosis Association of America (MSAA), has just…
What may be overlooked in relating to and caring for patients with multiple sclerosis is the fact that…